FDA's U-Turn On Fanapt: Comparative Assessments Must Have Clinical Meaning

The review of Vanda’s Fanapt casts into relief the contours of FDA’s authority to consider comparative efficacy as a factor in drug approval decisions.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet